After reviewing first-quarter results, we are maintaining our $56 per share fair value estimate for AptarGroup ATR. Following a few soft quarters in Aptar's important pharmaceutical segment, we were pleased to see solid margin expansion
AptarGroup ( ATR ): Q1 EPS of $0.64 misses by $0.02 . Revenue of $618M (+4% Y/Y) misses by $12.9M . ( PR ) Post your comment!
There have been many dispensing innovations in recent years, particularly in the consumer goods space, so we may have passed the peak of the current replacement cycle.Some pharmaceutical companies have taken drug delivery development in-house. If that trend intensifies, it could result in lower
sulfate cartonboard used in personal care and home packaging. For sprays, pumps, and dispensers, MeadWestvaco competes with AptarGroup ATR, Rexam REX, and some privately held companies. Due to this level of competition, we don't expect margins to meaningfully
AptarGroup ATR reported fourth-quarter sales of $571.4 million, representing an increase of 5% year over year; core sales (excluding
Ladies and gentlemen, thank you for standing by. Welcome to AptarGroup 's 2012 Fourth Quarter and Annual Results Conference Call. At this time, all participants are in a listen-only mode. Later
AptarGroup ( ATR ): Q4 EPS of $0.57 beats by $0.01 . Revenue of $571M (+5% Y/Y) beats by $14.54M . ( PR ) Post your comment!
Todd Wenning: Hi. I'm Todd Wenning, equity analyst at Morningstar, and I'm joined here today by Steve Hagge, CEO of AptarGroup . Steve, welcome. Steve Hagge: Thanks for having me. Wenning: Sure. My first question for you is: I was looking at
AptarGroup ATR reported third-quarter sales of $589.6 million, representing a decrease of 2% year over year; core sales (excluding
Nov 1 (Reuters) - Packaging products maker AptarGroup Inc said it would restructure its European operations after the company posted a quarterly profit below analysts' estimates due to soft demand in the region.